Oct 5, 2026 07:01AM
Sep 30, 2026 07:19AM
Sep 29, 2026 07:01AM
Sep 29, 2026 07:01AM
Sep 8, 2026 07:01AM
Sep 1, 2026 07:02AM
Sep 1, 2026 07:01AM Invivyd Appoints Chairman Marc W. Elia as Chief Executive Officer; Approaches Results of VYD2311 studies DECLARATION and LIBERTY
Aug 18, 2026 06:42AM
Aug 13, 2026 04:05PM
Aug 4, 2026 07:01AM
Jul 8, 2026 06:43AM
Jul 6, 2026 07:06AM
Jul 6, 2026 07:01AM
Jul 2, 2026 07:01AM Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Jun 29, 2026 07:00AM
Jun 16, 2026 07:01AM
Jun 16, 2026 07:01AM
Jun 9, 2026 07:01AM
Jun 9, 2026 07:01AM
Jun 3, 2026 07:01AM
Jun 1, 2026 07:02AM Invivyd completes enrollment in phase 3 COVID antibody trial
Jun 1, 2026 07:01AM
May 27, 2026 07:01AM
May 14, 2026 07:01AM
May 11, 2026 07:01AM
May 11, 2026 07:01AM
May 7, 2026 07:01AM
May 5, 2026 07:01AM Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Apr 20, 2026 07:01AM
Apr 9, 2026 07:03AM
Apr 9, 2026 07:01AM
Apr 6, 2026 07:01AM
Mar 30, 2026 04:05PM
Mar 5, 2026 07:03AM
Mar 5, 2026 07:01AM Invivyd names Michael Mina as chief medical officer
Mar 5, 2026 07:01AM
Mar 2, 2026 04:10PM
Mar 2, 2026 04:01PM
Feb 24, 2026 07:01AM
Feb 4, 2026 07:09AM
Feb 3, 2026 07:01AM
Feb 3, 2026 07:01AM Invivyd Aligns with the U.S. FDA on LIBERTY, a Phase 3 Trial to Evaluate the Safety of VYD2311 Antibody Versus mRNA COVID Vaccine, and to Characterize the Safety and Immunology of Antibody and Vaccine
Jan 22, 2026 07:01AM
Jan 22, 2026 07:01AM
Jan 20, 2026 07:01AM
Jan 20, 2026 07:01AM
Jan 8, 2026 07:08AM
Jan 8, 2026 07:01AM
Dec 23, 2025 07:05AM Invivyd receives FDA fast track status for COVID antibody VYD2311
Dec 23, 2025 07:05AM

333,310 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All